This is an aggregated industry headline. Read the full story at FierceBiotech →
Small pools, big ideas: How the rare disease community is reimagining clinical trials
The traditional gold standard of clinical trials with a randomized, placebo-controlled design involving hundreds of patients has inherently been unfeasible for the rare disease community.
By FierceBiotech
· Apr 17, 2026
· via FierceBiotech
Image: FierceBiotech
Tags
pipelineformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
PipelineFiercePharma ↗
With phase 3 results that have “exceeded” BioMarin’s expectations, the California biotech looks set up to gain…
PipelineFiercePharma ↗
According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with…
PipelineFiercePharma ↗
A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and …